Cryo-Cell International Reports $31.6 Million Revenue with Net Loss of $2.4 Million

Cryo-Cell International, Inc. reported a revenue of $31.6 million for the fiscal year ending November 30, 2025, a slight decrease of 1% from $32.0 million in the previous year. The decline in revenue was primarily attributed to a 12% drop in the number of new domestic cord blood specimens processed, despite a 3% increase in recurring annual storage fee revenue. The company's processing and storage fees accounted for the majority of its revenue, totaling $31.4 million, while product sales and public cord blood banking revenue contributed $54,104 and $129,513, respectively.

The company's financial performance was impacted by several operational changes. Cost of sales decreased by 7% to $7.4 million, reflecting reduced processing activity. Selling, general, and administrative expenses also saw a slight decline, totaling $18.2 million compared to $18.5 million in the prior year. However, the company recorded an impairment charge of $4.4 million related to public inventory, which was a significant factor in its net loss of $2.4 million for the year, compared to a net income of $402,095 in 2024.

Strategically, Cryo-Cell has faced challenges with its Duke University license agreement, which was intended to expand its business into new therapeutic areas. The company filed for arbitration against Duke in October 2024, alleging fraudulent inducement and breach of contract. Duke has counterclaimed, and the outcome of this dispute could significantly affect the company's future operations and financial health. As a result, the anticipated opening of the Cryo-Cell Institute for Cellular Therapies has been postponed, and the proposed spinoff of its subsidiary, Celle Corp., is also on hold.

Operationally, Cryo-Cell continues to manage over 250,000 cord blood and tissue specimens globally. The company has maintained a workforce of 72 full-time and 4 part-time employees as of November 30, 2025. The company’s cash and cash equivalents decreased to $319,031 from $560,960 in the previous year, reflecting its ongoing investments and operational expenditures. The company anticipates making discretionary capital expenditures of approximately $1 million over the next twelve months, primarily funded through cash on hand and its revolving line of credit.

Looking ahead, Cryo-Cell's management remains cautious about its financial outlook, particularly in light of the ongoing arbitration with Duke and the potential impacts on its business strategy. The company expects to continue focusing on its core services while navigating the uncertainties surrounding its licensing agreements and market conditions.